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Summary
TheT cell co-receptor, CD8, binds to the0 domain ofHLA class I (Salter, R.D.,R .J . Benjamin,
P.K . Wesley, S.E . Buxton, T.P.J . Garrett, C . Clayberger, A.M . Krensky, A.M . Norman, D.R .
Littman, andP Parham . 1990. Nature(Lond] . 345:41; Connolly,J.M ., TA . Potter, E.M. Wormstall,
andTH . Hansen. 1988 .J. ExpL Med. 168:325 ; and Potter, TA ., TV . Rajan, R.F. Dick II, and
J.A . Bluestone . 1989 . Natur e (Lond.j . 337:73) . To identify regions of CD8 that are important
for binding to HLA class I, we performed a mutational analysis of the CD8 molecule in the
immunoglobulin (1g)-like variable domain. Our mutational analysis was based on our finding
that using a cell-cell adhesion assay murine CD8 (Lyt-2) did not bind to human class I . Since
the interaction ofhuman CD8 withHLA class I is species specific, we substituted nonconservative
amino acids from mouse CD8 and analyzed the ability of the mutated CD8 molecules expressed
in COS 7 cells to bind HLA class I-bearing B lymphoblastoid cells, UC . Mutants with the
greatest effect on binding were located in a portion of the molecule homologous to the first
and second hypervariable regions of an antibody combining site. In addition, a panel of 12 anti-
CD8 monoclonal antibodies were used to stain the 10 CD8 mutants, and amino acids that affected
antibody binding were localized on the crystal structure of the BenceJones homodimer, REI .
Support for an Ig-like structure of CD8 can be found in the pattern of substitutions affecting
antibody binding. Thiswork supports the similar tertiary structure of theCD8 a-terminal domain
and an Ig variable domain .
T
he TCR-CD3 complex associates with CD8 or CD4 to
form a multimeric complex interacting with peptide and
HLA class I or HLA class II, respectively, duringT cell acti-
vation . In addition to their function as adhesion molecules,
CD8 and CD4 also serve as signalling molecules. The cyto-
plasmic domains of CD4 and CDSa bind to the NH2-
terminal domain of the intracellular tyrosine protein kinase
p56kk (1-3) . Antibody crosslinking ofCD8 and CD4 to the
TCR-CD3 complex leads to enhanced calcium flux and phos-
phorylation of a set of proteins, which includes the r chain
of the TCR complex (4-6) . The ability of CD8 to induce
these changes is dependent on its ability to associate with
p56kk . CD8 and CD4 are also important for positive and
negative selection in the thymus (7, 8) . TCR specificity in
T cell repertoire selection is determined by both the TCR-
a/(3 heterodimer and CD4 or CD8 accessory molecules
(9, 10) .
The human CD8 molecule is expressed either as an ala
homodimer or as an a/(3 heterodimer. The homodimer is
expressed exclusively on subsets of TCR-y/S cells and NK
cells, and is co-expressed with CD80 on peripheral T cells
and thymocytes . Individual human peripheral T cells can ex-
press varying amounts ofCD8 a/a and alai complexes, and
these appear to be differentially regulated uponT cell activa-
tion (11) . CD8 expression can be induced on human CD4
cells upon activation with mitogens (12) and on murine CD4
cells cultured in IL-4-containing medium (13) . Con A-acti-
vated y/S T cells that are CD4-8- can be induced to ex-
press the CD8 homodimer on a subset of cells . Thus, CD8
is differentially expressed during development, cell activation,
and in lymphocyte subsets.
Direct binding of CD8 to HLA class I and CD4 to HLA
class II was shown using cell-cell adhesion assays in which
CD8 or CD4 were expressed at high levels on the surface
ofchinese hamster ovary(CHO) cells forCD8 (14) or monkey
CV1 or COS 1 cells for CD4 (15, 16) . Purified class I and
CD8 molecules expressed in lipid-sealed spherical nylon vesicles
also showed specific binding (17) . The affinity of interaction
ofCD8 withMHC class I is increased upon activation through
the TCR (18) . Murine CTL were able to bind to an H-2
molecule on a planar membrane not recognized by the TCR
only afterT cell activation (18) . Thus, CD8 can bind to class
I in the absence of a TCR stimulus only when the levels of
CD8 are high .
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ofHLA class I affect binding ofCD8 to HLA class I (19-21) .
By mutational analysis, Salter et al . (19) found that a highly
conserved exposed loop involving residues 223-229 of the
0 domain ofHLA class I was important for binding . This
was considered a minimal CD8-binding site since two other
clusters of amino acids at positions 233 and 235, and posi-
tions 245 and 247 in the0 domain of HLA class I, were
also important for binding. The latter positions 245 and 247
were buried in the molecule and therefore considered unlikely
to be direct contact points (19) . In the mouse, residue 227
of H-2 class I molecules was shown to be important for rec-
ognition by CD8-dependent, but not CD8-independent,
CTL, implicating its role as part of a determinant that is
the ligand of the CD8 molecule (21) .
In this report, we performed a mutational analysis of the
CD8a molecule to determine what regions or amino acids
were important for binding to HLA class I and for anti-CD8
antibodies . We identified two regions of the CD8 molecule
that are important for the species-specific interaction ofCD8a
with HLA class I . These regions correspond to the CDR1
and CDR2 hypervariable regions of immunoglobulin REI
(22), known as the complementarity determining regions
(CDR) . These regions are not conserved between mouse and
human CD8 . Our work supports the hypothesis that there
may be additional binding sites in the 0 domain of HLA
class I besides the conserved loop (residues 223-229) that would
be important for species-specificCD8-HLA class I interaction .
Materials and Methods
DNA Constructs and Mutagenesis.
￿
Human CD8a cDNA (23)
was subcloned into the HindIII-BamHI site of Bluescript SK` .
Mouse CD8a was cut out of the PM7-CD8L vector (24) with
XbaI and Pstl and subcloned into the BamHI-Pstl sites ofBluescript
SK' . Human and mouse CD8 were excised from the Bluescript
vector with BamHI-HindIII, and HindIII-Xba I, respectively. The
inserts were blunted with the Klenow fragment of DNA poly-
merase I, ligated to EcoRI adaptors (New England Biolabs, Beverly,
MA), and subcloned into the EcoRI site of the pCDILSRa296
vectors (25) . CD8 mutants Ml-M10 were generated by oligo-
nucleotide-directed mutagenesis with single-stranded phagemid
DNA (26) .
Transfection ofCos7 Cells.
￿
Cos7 monkey kidney cells (27) were
transfected with SRa296 constructs (human CD8 wild-type and
CD8 mutants Ml-M10, mouseCD8 [Lyt-2], and vector alone) as
follows : 3 x 105 cells plated 24 h earlier in35-mm Primaria tissue
culture dishes (Falcon Labware, Oxnard, CA) were transfected with
5 hg plasmid DNA (CsCl-banded twice) in 1.0 ml OPTIMEM
plus 25 P,1 lipofectin (1 mg/ml) (Gibco-BRL, Gaithersburg, MD)
(28) . Lipofectin remained on the COS 7 cells for 18 h . Transfected
COS 7 cells were used 48 h later in the cell-cell adhesion assay
described below .
CD8-HLA Class I Cell-Cell Adhesion Assay .
￿
Transfected COS
7 cells were washed once with PBS and 10"SS-cysteine-labeled B
cells, UC (29), were added to each 35-mm dish in 1.0 ml PBS sup-
plemented with 10% heat-inactivated FCS, 100 U/ml penicillin-
streptomycin . The cells were incubated for 1 h at 37°C and the
B cells were poured off. The dishes were washed seven times by
adding 1 ml PBS containing FCS and plunking each dish from a
372 CDR 1- and CDR2-like Regions Affect Species-specific Binding
height of 3 inches. After washing the unbound B cells from each
dish, 0.6 ml PBS containing 1% NP-40 was added to each well .
Cells were incubated 20 min on ice, the NP-40 1ysate was removed,
and 50 ul was placed in aqueous scintillation flour and counted
to determine the number of B cells bound to the transfected COS
7 cells .
'SS-Cysteine Labeling ofB Cells.
￿
10s B cells were labeled with
1 mCi "S-cysteine (Amersham Corp., Arlington Heights, Ill) for
2 h at 37'C in cysteine-free RPMI containing 10% dialyzed FCS,
washed two times, and then used for binding as described above.
Approximately 50% of the "S-cysteine was incorporated into the
UC cells in 2 h, and the specific activity ranged from 7 to 12 cpm
per B cell.
Anti-CD8 Monoclonal Antibodies.
￿
A panel of 12 anti-CD8mAbs
were used to stain COS 7 cells transfected with the mutant CD8
molecules M1-M10 . The 10 mouse mAbs used were OKT8 (30),
51.1, 66.2, G17.5, G19.5, and G10 .1 (obtained from J . Ledbetter,
Bristol-Myers Squibb Research Institute, Seattle, WA), and Leu-
2a, Leu-2b, Leu-2c, and I eu-2d (Becton Dickinson&Co., SanJose,
CA) . The three rat anti-CD8 mAbs were Campath B and Cam-
path 8B, provided by H. Waldman (Cambridge University), and
the anti-murine CD8 antibody 53.6 (31) .
FACS® Analysis of TransfectedCOS 7 Cells.
￿
For FRCS® anal-
ysis, transfected COS 7 cells were removed from the dish with PBS
containing 0.6mM EDTA, stained with saturating concentrations
of anti-CD8 mAbs as described (32), and analyzed after staining
with either a 1:50 or 1:25 dilution of FITC-conjugated goat
anti-mouse IgG or goat anti-rat IgG (Southern Biotechnology,
Birmingham, Alabama) on a FACScan® (Becton-Dickinson&Co.) .
Propidium iodide was included to gate out dead cells. The FITC-
conjugated goat anti-mouse IgG or the goat anti-rat IgG served
as a negative control .
Analysis of Cell-Cell Adhesion Assay .
￿
Since the cell-cell adhe-
sion assay is transient, it was necessary to interpret the binding
not only in relationship to wild-type binding on that day, but also
to take into account the mean fluorescence intensities of theOKT8
antibody staining of mutants Ml-M7 and M9 or G19.5 antibody
staining for mutants M8 andM10 and the respective wild-type an-
tibody staining on that day. Therefore, the binding of UC cells
to COS 7 cells transfected with CD8 mutants was corrected for
binding ofUC cells to COS 7 cells transfected with vector alone
and was normalized for the linear mean fluorescence intensity (fl)
ofCOS 7 cells stained with mAb OKT8 (for mutants M1-7 and
M9) or mAb antibody G19.5 (for mutants M8 and M10) and for
the binding obtained with wild-typeCD8 . We used the following
formula (33) : 100 x % binding = [(mutant binding - vector
binding)/mutantOKT8 or G19.5 fl]/[(wild type binding - vector
binding)/wild type OKT8 or G19.5 fl] .
Results
Because the least homology between human and mouse
CD8 exists in the Ig-like domain (42% vs. 64-80% for the
cytoplasmic and transmembrane regions, respectively), we
hypothesized that this difference could lead to differences in
ability of these two molecules to bind to HLA class I . We
therefore transfectedcDNA for either mouse or human CD8
into COS 7 cells and determined whether these cells could
bind the HLA class I-expressing human B lymphoblastoid
cell line, UC, (29) . Detectable binding ofUC cells to human
CD8 expressing COS 7 cells could be observed using phase
contrast microscopy (Fig. 1 a), whereas minimal binding ofFigure 1 .
￿
Differences between mouse and human CD8 in binding to
MHC class I-expressing B cells . Phase contrast microscopy ofsmall, UC,
B cells bound to a monolayer ofCOS 7 cells transfected with human CD8
(a) or mouse CD8 (b) (x100) .
UC cells to COS 7 cells expressing mouse CD8 (Fig. 1 b)
or vector alone transfected COS 7 cells was observed (data
not shown) . This was not due to differences in expression
levels, becauseCOS 7 cells expressinghuman and mouseCD8
had similar mean fluorescence intensities after staining with
anti-CD8 antibodies (29 vs. 31 arbitrary units, respectively;
Fig. 2 a) .
Sincemouse CD8 did not bindhuman class I, we reasoned
that differences in amino acids in the variable-like region could
be important . Thus, we made a panel of 10 mutants by sub-
stituting nonconservative amino acids from mouseCD8 into
the human CD8 molecule from cysteine 22 to 94 (Fig. 3),
a portion ofthe variable-like region ofCD8 that is most likely
to resemble an Ig fold (34) . The mutants were transfected
into COS 7 cells and analyzed for binding to 35S-cysteine-
labeled B cells and a panel of 12 anti-CD8 mAbs .
CD8 mutants were grouped based on their effect on binding
to HLA class 1--expressingB cells, UC (Fig. 4) . Group 1(M2)
exhibited little or no binding of class I-expressing UC cells.
The percent relative wild-type binding was within the range
(-0.6-5.8%) of binding observed for mouse CD8-transfected
COS 7 cells. Group 2 (M1, M3, M5) bound low amounts
of HLA class I-expressing UC cells (9-16% of wild type) .
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FRCS® assayed CD8 expression (a-c) ofCOS 7 cells trans-
fected with murine or human CD8 (a), andCD8 mutants (b and c). (A)
FRCS® histogram ofCOS 7 cells transfected with murine CD8, stained
with rat mAb 53 .6 (31), or wild type humanCD8, stained with mouse
mAb, OKT8 (30), followed by second-step staining with FITC-conjugated
goat anti-rat IgG or goat anti-mouse IgG . Control cells are stained with
second-step antibody alone. (b) FRCS® histogram of OKT8 antibody
binding to COS7 cells transfected with wild-typehumanCD8 or mutant
M3 . The second-step reagent was FITC-conjugated goat anti-mouse IgG .
Control cells are stained with second-step antibody alone. (c) FACSO histo-
gram ofOKT8 antibody binding to COS 7 cells transfected with wild-
type human CD8 or mutant M4 stained as described above in b .
Group 3 (M6, M7, M9, M10) bound intermediate amounts
of class 1--expressing UC cells (31-57% ofwild type) . Group
4 (M4, M8) bound similarly to wild type (>80% of wild
type) . The percent relative binding was calculated with a cor-
rection for the level ofCD8 expression after transfection into
theCOS 7 cells since this variable has a direct effect on binding
(17) . However, even without this correction, the mutants fell
into similar groupings, except for M4, which would have
fallen into group 3 .
Mutant M2 (group 1) is a point mutant (leucine 26 to gly-
cine) that totally eliminated binding ofthe class I-expressing
UC cells relative to wild type (1.7% ± 1.02 ; Fig . 4) . Mu-
tant M2 was always expressed equal to or better than wild-
type, and the OKTS mAb staining profile was similar to that10
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of mutant M3 shown in Fig. 2 b . Since mutant M2 was ex-
pressed as well as wild-type CD8 and was a point mutant
that did not affect the staining of a panel of 12 anti-CD8
mAbs,we predict that mutantM2, which resides in the CDR1
Figure 4 .
￿
Binding of mutants to HLA class I-expressing B cells, UC,
relative to wild-type binding . Error bars represent SEM. There were two
to three experiments for each mutant. Between 9 .4 and 15.4% of theUC
cells bound to wild-typehuman CD8-transfectedCOS 7 cells, which was
4.2-9.2-fold above UC cells bound to vector alone . UC cells bound to
murine transfected COS 7 cells ranged from -0.6 to 5.8% compared to
wild-type . HumanCD8, murine CD8, and vector alone transfectedCOS
7 cells were included in each of seven experiments .
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Figure 3 .
￿
Sequence alignment ofhumanand murine CD8 with the Ig variable K light chain protein, REl . The top line shows the amino acid sequence
of the Ig-like variable region of human CD8 . The middle line shows the corresponding sequence of murine CD8 (48) . The bottom line shows the
variable region sequence of the BenceJones protein RE (37). Numbers indicate the amino acid number of the humanCD8 protein . Asterisks indicate
nonconservative amino acid changes between human and murine CD8 . Boxes indicate positions of mutants, Ml-M10, from left to right, except M6,
which changes the last two of the three amino acids changed in M7. The arrows under the REI sequence indicate the S strands of REI as determined
from the crystal structure (37). CDR1, CDR2, and CDR3 correspond to the Ig hypervariable regions (22) . Dots indicate positions where murine
CD8 or REI are identical to human CD8 . The sequence alignment requires relatively few insertions or deletions of residues with the exception of
a large insertion in the CDR2 and 0 strand C" regions ofCD8 making this region of the alignment the most uncertain .
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hypervariable-like region of Ig (22), is either defining a con-
tact point or is creating local conformational distortion .
Mutants Ml, M3, andM5 (group 2), exhibited low amounts
ofbinding to class I-expressing UC cells (M1 [15.65 ± 0.53],
M3 [13.5 ± 2.09], M5 [11 ± 2.4] ; Fig . 4) relative to wild
type . All three mutants in this group were expressed equal
to or better than wild type . Like mutant M2, mutant M5
bound all antibodies well . Mutant M5 has two amino acid
changes (glutamine 54 to histidine and lysine 58 to threo-
nine) located in the CDR2-like region . CD8 has many more
amino acids in this region compared with immunoglobulin
REI, so that if CD8 has an Ig-like structure, the L2 loop
is likely to be larger as compared with Ig. Mutant M1 has
two amino acid changes flanking cysteine 22 (lysine 21 to
valine and glutamic acid 23 to glutamine), which are located
in (3-strandB and CDR1 . This cysteine is likely to disulfide
bond to cysteine 33 since in mouse CD8 the cysteines at po-
sition 26 and 36 form a disulphide bond compatible with
an Ig fold (35) . Mutant M1 affected binding of anti-CD8
mAbs Leu-2c andCampath 8B (2% and 22.0%, respectively,
relative to wild-type staining; Table 1) . Because the amino
acid changes in mutant M1 flank cysteine 22, which is likely
to be involved in an intrachain disulfide bond and has two
anti-CD8 antibodies that are severely affected in their staining,
the total conformation of the CD8 molecule may have been
affected by this mutation . Mutant M3 resides in the CDR1
region and has two amino acid changes (asparagine 28 to va-Table 1.
￿
CD8 Antibody Staining Affected by CD8 Mutations
Percent relative linear mean fluorescence intensity
of CD8 antibody staining
Mutant
number 66.2 G17.5 Leu-2a Leu-2b Leu-2c Leu-2d Cam8B
A panel of 12 CD8 mAb was used to stain wild-type and mutant CD8
transsfected COS 7 cells . The 10 mouse mAbs were OKT8, 51.1, 66.2,
G10.1, G17 .1, G19.5, Leu-2a, Leu-2b, Leu-2c, and Leu-2d. The two
rat mAbs were campath B and campath 8B . Dashes indicate that the an-
tibody staining was equivalent to wild type . Mutants with mAb stain-
ing <50% of wild type are indicated by numbers .
line and serine 29 to proline, respectively) . The OKT8 mAb
staining profile for mutant M3 is shown in Fig . 2 b . Mutant
M3 abolished mAb 66.2 binding and reduced G17.5 mAb
binding to40% of wild type. Thus, mutants exhibiting low
amounts ofbinding reside in hypervariable-like regionsCDRI
and CDR2 .
Mutants M6, M7, M9, and M10 (group 3) exhibited in-
termediate amounts ofbinding ofclass 1--expressingUC cells
(M6 [49.1 ± 1.73], M7 [31.3 ± 0.28], M9 [56.9 ± 1.43],
M10 [42.6 ± 2.58] ; Fig . 4) . In this group, only mutant M7
was expressed as well as wild type, whereas mutants M6,
M9, and M10 were never expressed as well. For this reason,
we cannot be confident of the exact numbers obtained in the
binding assay. All we can say is that they do not exhibit low
amounts of binding to class I-expressing UC cells. Mutant
M6 changes two amino acids (glycine 62 to lysine and aspartic
acid 65 to asparagine) located inCDR2 andjust outside. Mu-
tant M7 has three amino acid changes, the same two as M6
with one additional amino acid change (alanine 60 to aspartic
acid) . Both mutants M6 and M7 abolished Leu-2d mAb
binding (Table 1) . Because mutant M7 has one additional
amino acid change at position 60 compared to mutant M6,
which has changes at positions 62 and 64, and exhibits 31%
binding compared to 49% forM6, this change from an aspartic
acid to an alanine may be more important for binding than
amino acids 62 and 64 . Alternatively, all three amino acids
may have an additive effect on binding . The binding ofmu-
tant M9 (phenylalanine 77 to asparagine; Fig . 3) was 57%
ofwild type, which could either be due to decreased expres-
sion or because ofits potential contact with loop 1 (36) (see
below) . Mutant 10, which had two amino acid changes
(aspartic acid 83 to lysine and proline 85 to serine, respec-
tively) bound 43% relative to wild type and was negative
for binding of the two antibody epitopes, Leu-2b and Leu-2d .
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Figure 5 .
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Location of residues in the variable region ofCD8 affecting
binding of anti-CD8 antibodies on the a-carbon skeleton derived from
coordinates of the Vu BenceJones homodimer, RE (37) . The diagram
was generated using the program RIBBON (49) . One member of the
dimer is shown . Numbers 1, 2, and 3 on the diagram refer to the hyper-
variable loops Ll, L2, and L3 (36), and the lettersA-G indicate the 0
strands. The sheet forming the VL dimer interface is distant from the
viewer. The numbered positions indicate REI residues corresponding to
the amino acid substitutions in mutantsMl (22, 24), M3 (29, 30), M6/7
(54, 56, 58), M8 (64, 65), M9 (between 70 and 71), and M10 (77, 79),
which affected the following anti-CD8 mAbs, respectively (see Table I) :
Leu-2c and cam8B, 66.2 and G17.5; Leu-2d, Leu-2a, G17 .5 ; Leu-2b and
Leu-2d. There is no corresponding REI residue for mutant M9 (see Fig.
3), therefore, REI residue 70 located on one side of the mutant is labeled.
The biggest discrepancy between RE and CD8 is in the L2 and # strand
C" due to a large insertion in CD8 . It is likely that to accommodate the
extra amino acids in CD8, the L2 loop would be more extensive and would
project towards the other hypervariable loops Ll and L3 .
It was also partially affected for OKT8 mAb staining (70%
ofwild type) . The multiple effects on antibody binding could
reflect overlapping epitopes or a disruption of overall stability.
Mutants M4 (proline 39 to asparagine and arginine 40 to
serine) andM8 (glycine 70 to alanine and lysine 71 to methi-
onine) were not affected in their binding to class I-expressing
UC cells (Fig . 4) . Mutants M4 andM8 were never expressed
as well as wild type. An example of the OKT8 mAb staining
profile for mutant M4 is shown in Fig. 2 c . Of these two
mutants, only M8 did not bind all mAbs well . Mutant M8
destroyed Leu-2a mAb binding (Table 1) .
The protein sequence of CD8 was aligned with that of
the REI light chain using conserved IgG residues as a guide .
A molecular model for theCD8 cx/ahomodimer was gener-
ated using the REI light chain dimer crystal structure as a
Ml - - - - 2.0 - 22.0
M3 3.0 40.0 - - - - -
M6 - - - - - 4.0 -
M7 - - - - - 4.0 -
M8 - - 4.0 - - - -
M9 - 22.0 - - - - -
M10 - - - 1.2 - 1 .9 -three-dimensional template (37). Side chain substitutions were
made using the graphics program INSIGHT II, and internal
packing of the structure was defined and analyzed using the
program PICOPAK (38) . Despite the low level of sequence
identity, the internally packed residues were replaced by like
hydrophobic side chains leading to an efficient repacking of
the protein interior. Small repositioning of the backbone was
required to accommodate general internal side chain substi-
tutions. Amino acid substitutions at theREI light chain dimer
interface were also conservative resulting in a well-packed ex-
tended surface suggesting that this mode of interaction is a
valid model for the CD8 a/ci homodimer interface.
Based on modelling with REI, we located the relative po-
sitions of amino acid changes that affected antibody binding .
In most cases, antibody binding was affected by a single mu-
tant, whereas in two cases, mutants in different locations were
affected . All amino acid positions affecting antibodybinding
were available to the solvent and presumably could bind an-
tibodies (Fig. 5) . Mutants M3 and M9 both reduced G17.5
antibody staining to 40 and 22%, respectively, relative to wild
type. Mutant M3 is located in CDR1 and corresponds to
REI positions 29 and 30, whereas mutant M9 is either in
the loop between R strands DE or located in a strandE (Fig .
3) . These two regions may be in close proximity if the loop
extends into the loop between (3 strands B and C (Fig. 5) .
Mutants M6, M7, and M10 all affected Leu-2d antibody
staining. Mutants M6 andM7 are more difficult to position
because of the extra amino acids in CD8 compared with REI
in this region . Given this caveat, their position either in (3
strand C" or between 0 strands C"D is spatially close to the
position of mutant M10 lying betweena strands EF. Thus,
the location ofmutants affecting the samemAb that are spa-
tially distant on a linear map are spatially close on a three-
dimensional model ofCD8 based on Ig structure. These results
support the hypothesis that the CD8 structure is similar to Ig .
Discussion
A mutational analysis of amino acids in CD4 important
for MHC class II binding has also been reported (16, 39) .
Mutations in the CDR1- and CDR2-like regions as well as
outside the predicted CDR loops affected binding (16) . How-
ever, the strongest effects were observed for mutations in the
CC' and C"D corners of domain 1 and along the A strand
of domain 2 of the four Ig-like domains in CD4 . This led
to the hypothesis that the CD4-MHC class II interaction
would be similar to Ig but not exclusively Ig like. A genetic
analysis ofmAb and HIV binding sites onCD4 also affirmed
the similar tertiary structures of the CD4 NH2-terminal do-
main and Ig variable regions (40) . Our results onmAb binding
and binding toMHC class I for CD8 are best explained by
invoking an Ig-like structure for CD8 as well .
After completion of this work, two reportson the crystal-
lization of the outer two domains of CD4 were published
(41, 42) . In this very exciting work, the Ig-like structure of
both domains was established. Domain 1 (98 amino acids),
which is similar in size to an Ig domain, has nine (3 strands
folded like a "sandwich" with a hydrophobic core. The major
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differences with Ig lie in the loops . For instance, the turn
between strands CC' and FG is shorter. These regions are
thought to be important in the dimer formation of an Ig
molecule, and the FG loop contains the CDR3-like region
important for antigen binding. These regions would presum-
ably not be necessary for CD4, which is a monomer. Be-
cause CD4 mutations in the CC' and C"D comers of do-
main 1 along with theA strand of domain 2 had the strongest
effect on binding, it was proposed that thetwo domainsmay
form a notch for interlocking CD4 withMHC class II (41) .
The regions of interaction with MHC may be different
betweenCD4 and CD8 . In contrast to CD4, CD8 is a dimer
as is Ig. Interestingly, thetwo shortened regions in CD4 be-
tween strands CC' andFG are not shortened in CD8 . There-
fore, the CDR3-like region would be available as a site of
interaction in CD8 . We found that the mutation in CD8
with the greatest effect on binding toMHC class I, mutant
M2, which was a leucine to glycine substitution, was located
in the CDR1-like region. Therefore, in our work both the
CDR1 and CDR2 regions ofCD8 appear to be important
for MHC class I binding .
We would therefore postulate that the CDR1- and CDR2-
like regions ofCD8a are important for species-specific inter-
action of CD8a with HLA class I and that an additional
region such as the CDR3-like region is also involved in
binding. Because the CDR3-like region is highly conserved
between murine and human and lacks nonconservative
changes, this would suggest that it is not involved in species
specificity ofbinding . Instead, this may be the region binding
to the conserved loop from position 223-229 in the0 do-
main ofMHC class I important for CD8 binding (19) . The
residues in this loop are identical betweenmouse andhuman
except at position 228, which contains a methionine instead
of a threonine. If this region binds to a conserved region of
CD8, then theCDR3 domain (Fig. 3, L3) is the region most
likely tomake contact with the 223-229 loop given the likeli-
hood that CD8 has an Ig-like structure as does CD4, and
given the importance of the loops as sites ofinteraction with
other molecules . In addition, our data would support the
findings that there are additional amino acids in the0 do-
main ofHLA important for contact withCD8 besides those
in the conserved loop from position 223-229 (19) .
From the analyses ofT cell responses toMHC class I, a
species-specific interaction between murine CD8 and the0
domain ofMHC class I was proposed (43, 44) . The majority
of A2-specific murine CTL clones induced by stimulation
with A2-expressing human stimulator cells showed enhanced
recognition of target cells expressing the human-murine chi-
meric molecule A2/Kb, and this enhanced recognition of
A2/Kb was sensitive to inhibition by anti-CD8 antibody
(43) . This was also the case for stimulation ofCTL precursors,
which implied that properties of the0 domain were also
important forT cell activation. Kalinke et al . (44) produced
transgenic mice with chimeric al and cx2 domains ofHLA-
B27 and the0 domain of the mouse Lyt-2 molecule, and
demonstrated that the spleen T cells responded to the chi-
meric molecule at a frequency characteristic of an allogeneic
response. They demonstrated that the poor response toxenogeneic MHC class I molecules resulted from the ina-
bility of the mouse CD8 co-receptor to interact with the
human MHC molecule. Our results using a cell-cell adhe-
sion assay are consistent with these findings.
In contrast, human CD8a was reported to bind to either
murine or humanMHC class I molecules (45) using a cell-
cell adhesion assay . Murine and human MHC class I mole-
cules were transfected into the human A - , B` class I cell
line, CIR, and binding to CHO expressing high levels of
CD8 was determined . Good binding to either murine or
human molecules was observed . However, the conformation
of mouse class I heavy chains associated with human a2-
microglobulin may not be equivalent to mouse class I heavy
chains paired with mouse R2-microglobulin. For instance,
the human class I W6/32 antibody epitope is lost when fj2-
microglobulin from mouse pairs with thehuman class I heavy
chain (46) . Further work is required to affirm this difference
between the human and mouse CD8 molecule.
This is the first report of a cell-cell adhesion assay using
a transient CD8 expression system in COS 7 cells to detect
binding toHLA class I-expressing B cells. The lipofectin re-
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